Baxter International (BAX)
34.51
-0.42 (-1.20%)
Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care
The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide.
Previous Close | 34.93 |
---|---|
Open | 34.95 |
Bid | 34.30 |
Ask | 35.28 |
Day's Range | 34.00 - 35.17 |
52 Week Range | 28.33 - 44.01 |
Volume | 4,780,015 |
Market Cap | 17.25B |
PE Ratio (TTM) | -26.96 |
EPS (TTM) | -1.3 |
Dividend & Yield | 1.160 (3.36%) |
1 Month Average Volume | 5,287,486 |
News & Press Releases

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSESYK).
Via StockStory · February 28, 2025

Healthcare is the top-performing sector in the market, up 7.31% and outperforming the S&P 500 by 4.2x. Looks like the rumors of its death were indeed GREATLY EXAGGERATED.
Via Talk Markets · February 27, 2025

Via Benzinga · February 26, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSEBAX).
Via StockStory · February 25, 2025

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
By Baxter International Inc. · Via Business Wire · February 25, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · February 24, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQNEOG) and its peers.
Via StockStory · February 24, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · February 20, 2025

Healthcare company Baxter International (NYSEBAX) beat Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $2.75 billion. On the other hand, next quarter’s revenue guidance of $2.58 billion was less impressive, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was significantly above analysts’ consensus estimates.
Via StockStory · February 20, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · February 20, 2025

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via Chartmill · February 20, 2025

Baxter International exceeded Q4 earnings and revenue estimates, with strong pharmaceutical sales. The company issued a mixed 2025 outlook amid cost pressures.
Via Benzinga · February 20, 2025

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2024, and provided its financial guidance for first-quarter and full-year 2025.
By Baxter International Inc. · Via Business Wire · February 20, 2025

Healthcare company Baxter International (NYSEBAX)
will be reporting earnings tomorrow morning. Here’s what investors should know.
Via StockStory · February 19, 2025

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:10 p.m. Eastern Time.
By Baxter International Inc. · Via Business Wire · February 18, 2025

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Raymond James & Associates’ 46th Annual Institutional Investors Conference on Monday, March 3, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:05 p.m. Eastern Time.
By Baxter International Inc. · Via Business Wire · February 17, 2025

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Citi - 2025 Medtech & Life Sciences Access Day on Thursday, February 27, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
By Baxter International Inc. · Via Business Wire · February 13, 2025

Healthcare company Baxter International (NYSEBAX)
will be announcing earnings results tomorrow morning. Here’s what investors should know.
Via StockStory · February 12, 2025

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on April 1, 2025, to stockholders of record as of Feb. 28, 2025. The indicated annual dividend rate is $0.68 per share of common stock.
By Baxter International Inc. · Via Business Wire · February 11, 2025

Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.
Via Benzinga · February 7, 2025

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025.
By Baxter International Inc. · Via Business Wire · February 3, 2025

Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options
By Vantive · Via GlobeNewswire · February 3, 2025

Via Benzinga · January 27, 2025